EGFR and non-small cell lung carcinoma: These rapid advances in EGFR targeted therapies have led to improved clinical outcomes;16, 17, 18 however, the associated increased cost renders cost‐effectiveness studies critical, particularly in public healthcare systems.19, 20, 21 Cost‐effectiveness studies rely on quality‐adjusted life years, which are based on health utility scores (HUS).22 However, HUS data are sparse in the EGFRm NSCLC population for several reasons.